Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies

Tanaka, Junji

doi:10.1002/hon.2802

Cited by 5 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tri-specific antibodies providing co-stimulatory and activating signaling are new candidates for cancer treatment [39]. Meanwhile, CAR natural killer cells immunotherapy is also a potential approach for the treatment of ALL [40, 41]. Hence, it is optimistic that more potential immunotherapies are required to be developed for the treatment of pediatric ALL.…”

Section: Challenges and Outlookmentioning

confidence: 99%

Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects

Zhang

Kankala

et al. 2022

Pharmacology

View full text Add to dashboard Cite

Background: Acute lymphoblastic leukemia (ALL) is one of the most commonly diagnosed cancers in children. Despite enormous efforts to treat ALL over the past decade, the intensity of conventional chemotherapeutic strategies has reached the tolerance limit. Among various recently developed therapeutic approaches, antibody and cellular-based therapies showed less toxicity and better curative effect. Summary: Due to advanced mechanistic actions, these innovative therapies have provided durable responses and long-term survival in eradicating pediatric ALL, especially patients with refractory/relapsed ALL. Owing to these aspects, herein, we emphasize the mechanisms of action and application status of antibodies targeting tumor antigens, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T cells. Key Messages: The significant prospects and challenges are discussed, highlighting the innovative immunotherapies to deal with ALL. Together, this review will summarize the progress of antibody and cellular-based therapies for pediatric ALL, which may promote further research on antibody-based biopharmaceutics.

show abstract

Section: Challenges and Outlookmentioning

confidence: 99%

Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects

Zhang

Kankala

et al. 2022

Pharmacology

View full text Add to dashboard Cite

show abstract

“…CAR-NK cells also have some advantages, including 1. There are many sources of NK cells (10)(11)(12), such as NK cell lines, peripheral blood, cord blood and induced pluripotent stem cells (iPSCs), especially NK92 cells (13)(14)(15); 2. Higher security.…”

Section: Introductionmentioning

confidence: 99%

A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022

2022

View full text Add to dashboard Cite

ObjectivesAs emerging adoptive immunotherapy after CAR-T cell therapy, CAR-NK cell therapy has been developing rapidly in recent years. Presently, the research on CAR-NK cells has become a hotspot in the field of tumor immunotherapy.MethodsIn this descriptive study, CtieSpace and VOSviewer were used to perform the bibliometric and scientific knowledge-map analysis of articles and reviews related to CAR-NK cells.Results5371 authors from 715 institutions in 65 countries published 1028 papers about CAR-NK cells in 346 journals. The number of publications related to CAR-NK cells was increasing overall, especially from 2018 to 2021. The United States was in a leading position. The most active institution was Univ Texas, MD Anderson Cancer Center (USA). The journal with the most publications was Frontiers in immunology, and the most co-cited journal was Blood. The researcher with the most published papers was Winfried S. Wels, while the most co-cited researcher was Shannon L Maude. The research of CAR-NK cells in hematological malignancies and solid tumors (especially the selection of targets and the evaluation of efficacy and safety) was a research hotspot in this field. The emerging topics mainly included three aspects. First, further improve the proliferation and persistence of NK cells in vivo. Secondly, optimizing and improving the CAR structure for NK cells to improve the anti-tumor ability of CAR-NK cells. Thirdly, the related research of CRISPR/Cas9 gene-editing technology in constructing engineered immune cells.ConclusionIn this study, a bibliometric and scientific knowledge-map study provided a unique and objective perspective for the CAR-NK cell field. This information would provide a helpful reference for researchers interested in this field.

show abstract

“…In the past decade, cellular therapy has become a paradigm‐shifting arsenal for hematological malignancies. Chimeric antigen receptor (CAR) is a synthetic receptor 4 . The first generation CAR consists of a T cell activation domain (usually including the Zeta chain of the CD3 complex) and an extracellular tumor‐associated antigen binding domain.…”

Section: Introductionmentioning

confidence: 99%

Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives

et al. 2022

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B-cell malignancies, many studies have attempted to translate this success to other malignancies, including AML. Herein we review current achievements of chimeric antigen receptor-based cell therapy in AML preclinical studies and clinical trials with potential AML-associated cell markers. Furthermore, we discuss future prospects of chimeric antigen receptor-based cell therapy options for patients with AML.

show abstract

Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies

Cited by 5 publications

References 56 publications

Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects

Antibody and Cellular-Based Therapies for Pediatric Acute Lymphoblastic Leukemia: Mechanisms and Prospects

A bibliometric and scientific knowledge-map study of the chimeric antigen receptor (CAR) natural killer (NK) cell-related research from 2010 to 2022

Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives

Contact Info

Product

Resources

About